Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is demonstrating strong progress in their clinical trials for 4D-150, supported by an experienced leadership team and a competitive pipeline in larger indications. At $26 per share, their current valuation is based on probability-adjusted modeling, which projects $484.6 million in peak sales for wet AMD and $123.2 million for DME by 2034. The company may face challenges in manufacturing and future financing, but the potential for a significant market share in these indications makes 4D Molecular Therapeutics an attractive investment.

Bears say

4D Molecular Therapeutics is a biotechnology company with a focus on developing gene therapies for eye and lung diseases. However, the negative outlook on the company's stock is based on concerns about the potential for competition from other emerging therapies, the risk of setbacks in clinical trials, and the possibility of delays in the development and commercialization of their products due to the complexity of manufacturing gene therapies. Additionally, there are uncertainties surrounding the potential market size for their products and their ability to compete with established treatments in the market. The current estimated peak sales for one of their key products, 4D-710 for cystic fibrosis, is $527.6mm in 2034E. Given these factors, there is a high level of risk associated with investing in the company, which warrants a negative outlook on the stock.

FDMT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 7 analysts, FDMT has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.